Dual effects of atorvastatin on angiogenesis pathways in the differentiation of mesenchymal stem cells

• Published in: European journal of pharmacology 2021-09, Vol.907, p.174281, Article 174281
• Main Authors: Khalighfard, Solmaz, Khori, Vahid, Alizadeh, Ali Mohammad, Vahabzadeh, Gelareh, Tajaldini, Mahboubeh, Sedighi, Sima, Nozarian, Zohreh, Khodayari, Hamid, Khodayari, Saeed, Ganji, Fatemeh, Veisi Malekshahi, Ziba, Mirmajidi, Tahereh
• Format: Article
• Language: English
• Subjects: Angiogenesis; Angiogenesis pathways; Animals; Atorvastatin; Atorvastatin - pharmacology; Cell Differentiation - drug effects; Cell Proliferation - drug effects; Male; Matrigel; Mesenchymal stem cell; Mesenchymal Stem Cells - cytology; Mesenchymal Stem Cells - drug effects; Mesenchymal Stem Cells - metabolism; Mice; Mice, Inbred BALB C; Neovascularization, Physiologic - drug effects; Osteogenesis - drug effects; Signal Transduction - drug effects; Vascular Endothelial Growth Factor A - genetics; Vascular Endothelial Growth Factor A - metabolism
• ISSN: 0014-2999; 1879-0712; 1879-0712
• DOI: 10.1016/j.ejphar.2021.174281

Atorvastatin (ATO) can improve the transplantation efficacy of mesenchymal stem cells (MSCs) after acute myocardial infarction. The present study aimed at ATO effects on the angiogenesis-signaling pathways from MSCs' differentiation to tissue angiogenesis. MSCs were first prepared from BALB/c mouse bone marrow. MTT assay was then done for the biodegradability of MSCs with the extracellular matrix. After that, the differentiation of cells into the bone and fat tissues was confirmed by Alizarin and Oil Red O staining. The extracellular matrix was then combined with the cells to the implant. Animals were intraperitoneally treated with ATO (2 and 40 mg/kg, daily) three days before cell transplantation to one week after. Finally, the assays were carried out by electron microscopy, immunocytochemistry, ELISA, Western blot, and RT-qPCR techniques. A phase-contrast microscope confirmed the morphology of cells. The cell differentiation into bone and fat tissues was confirmed by Alizarin red staining and flow cytometry, and the cell proliferation was confirmed by MTT assay. Unlike ATO 40 mg/kg group, ATO 2 mg/kg was significantly increased the CD31, eNOS, podocalyxin, von Willibrand factor, and alpha-smooth muscle actin proteins levels compared to the control group in vitro experiment. The expression of CD31 and VEGF proteins, as angiogenesis markers, and Ki-67 protein, as a proliferation marker, was significantly higher in a low dose of ATO (2 mg/kg) than that of the control group in vivo experiment. Unlike ATO 40 mg/kg, the expression levels of ERK, AKT, NF-ҝB, Rho, STAT3, Ets-1, HIF-1α, and VEGF proteins and genes were significantly increased in ATO 2 mg/kg compared to the control. A low dose of ATO can be a beneficial tool in the function of MSCs and their differentiation to tissue angiogenesis.